Skip to main content
Back
CHSYF logo

China Medical System Holdings Limited

Data quality: 100%
Overbought
CHSYF
OTC Healthcare Drug Manufacturers - Specialty & Generic
$1.35
$0.00 (0.00%)
Mkt Cap: 3.28B
Day Range
$0.93 $1.35
52-Week Range
$0.93 $1.64
Volume
110
50D / 200D Avg
$1.35 / $1.31
Prev Close
$1.35

Quick Summary

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (633 peers)

Metric Stock Sector Median
P/E 2.3 0.2
P/B 0.2 2.8
ROE % 8.6 3.7
Net Margin % 18.1 3.9
Rev Growth 5Y % -1.0 10.0
D/E 0.0 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2028 $1.23
$1.11 – $1.31
 14.83B 1
FY2027 $1.01
$0.91 – $1.07
 11.99B 1
FY2026 $0.85
$0.76 – $0.90
 9.98B 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-16 $0.30 $0.03 -89.3%
2025-08-18 $0.05 $0.05 +5.1%
2025-03-17 $0.05 $0.04 -14.1%
2024-08-15 $0.04 $0.05 +16.7%
2024-05-09 $0.08 $0.03 -63.7%
2023-06-30 $0.10 $0.11 +8.9%
2022-12-31 $0.09 $0.09 -4.7%
2022-06-30 $0.11 $0.11 -1.0%

Dividend History

7 yr streak

Yield

0.03%

Payout Ratio

0.44%

Growth (3Y)

-20.87%

Growth (5Y)

-4.80%

Ex-Date Payment Date Amount Yield
Apr 27, 2026 May 07, 2026 $0.02 4.28%
Sep 02, 2025 Sep 09, 2025 $0.02 2.81%
Apr 30, 2025 May 09, 2025 $0.02 5.18%
Aug 30, 2024 Sep 09, 2024 $0.02 3.45%
May 15, 2024 May 23, 2024 $0.01 2.34%
Sep 11, 2023 Sep 20, 2023 $0.04 5.13%
May 03, 2023 May 12, 2023 $0.03 4.81%
Sep 05, 2022 Sep 15, 2022 $0.04 4.82%
Apr 26, 2022 May 06, 2022 $0.03 4.75%
Sep 08, 2021 Sep 15, 2021 $0.04 3.80%
Apr 29, 2021 May 10, 2021 $0.03 2.82%
Aug 26, 2020 Sep 04, 2020 $0.03 3.86%
Jun 08, 2020 Jun 17, 2020 $0.02 3.52%
Aug 30, 2019 Sep 10, 2019 $0.03 4.92%
Apr 29, 2019 May 09, 2019 $0.02 5.09%
Sep 10, 2018 Sep 19, 2018 $0.02 2.57%
Apr 30, 2018 May 10, 2018 $0.02 2.12%
Sep 04, 2017 Sep 13, 2017 $0.02 2.22%
Apr 28, 2017 May 12, 2017 $0.02 2.27%
Sep 02, 2016 Sep 15, 2016 $0.02 1.97%

Key Takeaways

Revenue declined -1.03% annually over 5 years
Earnings declined -10.45% over the past year
Net margin of 18.13% shows strong profitability
Debt/Equity of 0.04 — conservative balance sheet
Generating 812.64M in free cash flow
P/E of 2.26 — trading at a low valuation

Growth

Revenue Growth (5Y)
-1.03%
Revenue (1Y)7.11%
Earnings (1Y)-10.45%
FCF Growth (3Y)-48.20%

Quality

Return on Equity
8.60%
ROIC6.37%
Net Margin18.13%
Op. Margin19.22%

Safety

Debt / Equity
0.04
Current Ratio6.33
Interest Coverage77.77

Valuation

P/E Ratio
2.26
Forward P/E1.59
P/B Ratio0.19
EV/EBITDA0.82
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 7.11% Revenue Growth (3Y) -0.08%
Earnings Growth (1Y) -10.45% Earnings Growth (3Y) -22.27%
Revenue Growth (5Y) -1.03% Earnings Growth (5Y) -16.73%
Profitability
Revenue (TTM) 8.00B Net Income (TTM) 1.45B
ROE 8.60% ROA 7.55%
Gross Margin 71.50% Operating Margin 19.22%
Net Margin 18.13% Free Cash Flow (TTM) 812.64M
ROIC 6.37% FCF Growth (3Y) -48.20%
Safety
Debt / Equity 0.04 Current Ratio 6.33
Interest Coverage 77.77
Dividends
Dividend Yield 0.03% Payout Ratio 0.44%
Dividend Growth (3Y) -20.87% Dividend Growth (5Y) -4.80%
Consecutive Div Years 7 yrs
Valuation
P/E Ratio 2.26 Forward P/E 1.59
P/B Ratio 0.19 P/S Ratio 0.41
PEG Ratio -1.51 Forward PEG N/A
EV/EBITDA 0.82 Fwd EV/EBITDA 0.36
Forward P/S 0.33 Fwd Earnings Yield 62.89%
FCF Yield 24.80%
Market Cap 3.28B Enterprise Value 1.26B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 8.00B 7.47B 8.01B 9.15B 8.34B
Net Income 1.45B 1.62B 2.40B 3.26B 3.02B
EPS (Diluted) 0.60 0.67 0.98 1.33 1.22
Gross Profit 5.72B 5.42B 6.08B 7.04B 6.25B
Operating Income 1.54B 1.73B 2.71B 3.55B 3.15B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19.21B 18.05B 17.73B 17.75B 15.81B
Total Liabilities 1.66B 1.64B 2.17B 3.02B 2.96B
Shareholders' Equity 17.40B 16.31B 15.52B 14.59B 12.75B
Total Debt 690.43M 860.74M 1.30B 1.81B 1.71B
Cash & Equivalents 2.70B 3.71B 4.31B 4.38B 3.39B
Current Assets 9.30B 8.70B 8.79B 8.83B 7.38B
Current Liabilities 1.47B 1.52B 2.05B 2.88B 2.08B

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#708 of 834
23

Recent Activity

Exited Defensive Investing (Benjamin Graham)
Mar 26, 2026
Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026